Recommend PSMA radioligand therapy before chemotherapy for patients who (i) meet imaging criteria for PSMA radioligand ...

Sotorasib was the first approved KRAS inhibitor granted marketing authorisation by the US Food and Drug administration (FDA) ...

Tecentriq plus Cabometyx conferred no overall survival benefit when compared with chemotherapy, a study showed.

Advanced Prostate Cancer Consensus Conference (APCCC) meeting featured a session on the management of metastatic CRPC (mCRPC) ...

Jacobio Pharma has reported the results of its pivotal Chinese study of KRAS G12C inhibitor glecirasib, with a safety profile ...

Merck & Co Inc (NYSE: MRK) announced full results from the Phase 2 KeyVibe-002 trial of vibostolimab/pembrolizumab combo, with or without docetaxel for metastatic non ...

Combining chemotherapy and hormonal therapy for patients with locally advanced prostate cancer provides longer control of ...

Matinas' Positivein vivo Safety Data with its Oral LNC-Docetaxel Formulation BEDMINSTER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical ...

My name is Towanda, and I will be your operator today. As a reminder, this call is being recorded for replay purposes. I ...

Abiraterone acetate plus prednisone and enzalutamide improve overall survival (OS) and radiological progression-free survival (rPFS) in docetaxel-pretreated patients. Abiraterone acetate plus ...

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to ...